12,372 trials
Asthma
Primary: Percentage of Participants With Successful Self-administration of Their Observed Third Dose at Week 8 - Autoinjector With Standard Label + Pictogram — 99 Percentage of…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -1.04; -1.10 Percentage of glycosylated hemoglobin — p=<0.0001
Cancer Malignancies
Primary: Neurocognitive Function as Measured by Performance on Standardized Tests of Attention, Memory, and Executive Function. — 0.35; 0.18; 0.06; 0.37 Z-score
Rubella · Measles · Mumps
Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 98.2; 98.9; 98.1; 98.1 Percentage of subjects
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -23.9; -22.8; -17.5 units on a scale — p=<0.001
Hyperkalemia
Primary: Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase — 77.9 Percentage of…
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) by Week 19 — 45.3; 44.6 percentage of participants
Plaque Psoriasis
Primary: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) — 65.6; 61.2; 5.8; 48.2 Percentage of participants…
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Percentage of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 1.0 µg/mL — 98.2; 97.2 Percentage of subjects
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Acute Leukemias of Ambiguous Lineage · Bacterial Infection · Diarrhea
Primary: Comparison of the Percentage of Patients Having Bacteremia Incidence Between Levofloxacin vs. No Prophylaxis Arms — 21.9; 43.4; 11; 17.3 Percentage of patients
Prostate Cancer
Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40
Breast Cancer
Primary: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms — -3.4; -1.4 percent change
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) (Week 26) — -0.23; 0.17 Percentage (%) of HbA1c — p=<0.0001
Migraine
Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -1.84; -2.88 migraine days / month — p=< 0.001